一个多种药丸的成本效益,用于预防心血管疾病,在一个欠缺服务的人群中
Ciaran N Kohli-Lynch1, Andrew E Moran2, Dhruv S Kazi3,4
1Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
JAMA cardiology
|January 8, 2025
概括
心血管多药治疗是对低收入,占多数的黑人人口的高价值干预,以每QALY可接受的成本获得显著的质量调整寿命年 (QALYs). 这种方法可以减少心血管疾病 (CVD) 的差异.
科学领域:
- 卫生经济学 卫生经济学
- 预防心血管疾病预防心血管疾病
- 在健康方面存在差异.
背景情况:
- 南方社区队列研究 (SCCS) 多药丸试验证明了心血管多药丸在控制心血管疾病 (CVD) 风险因素中的有效性,主要是黑人,低收入人口.
- 在这个特定的人口群体中,这种多药药策略的成本效益尚未先前评估.
研究的目的:
- 评估心血管多药丸与低收入,多数为黑人人口的常规护理相比的成本效益.
- 确定多药治疗在减少心血管疾病风险因素和改善健康结果方面的经济价值.
主要方法:
- 基于已建立的CVD政策模型的离散事件模拟模型被用于分析10年期间的临床和经济结果.
- 该模拟结合了来自多项大型调查和队列研究的数据,包括SCCS多药试验,以建模两个队列:试验代表组和所有符合条件的非西班牙裔美国黑人成年人.
- 根据直接医疗成本和质量调整寿命年 (QALYs) 评估了成本效益,并进行了灵敏度分析来测试模型的稳定性.
主要成果:
- 在10万个代表SCCS多药药试验的人群中,多药治疗预计与通常护理相比平均获得1190个QALY,每获得QALY的增量成本为8,560美元,表明高价值.
- 如果每年价格为559美元或更低,多药药治疗被发现是具有成本效益 (高价值),如果价格为443美元或更低,则节省成本.
- 在对超过360万符合条件的非西班牙裔黑人成人的更大分析中,多药治疗仍然是一个高价值的干预措施,估计每QALY获得的成本为13,400美元.
结论:
- 这些发现表明,心血管多药治疗对低收入,多数黑人人口,特别是那些获得医疗保健有限的人群来说,是一种高价值的医疗干预措施.
- 实施多药药治疗可能会减少这一群体内的健康差异.
- 成本效益是有利的,特别是在较低的价格点上,支持其作为改善心血管健康结果的战略.
相关概念视频
01:30Preventive Healthcare Services
960
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
960
01:26Levels of Health Promotion and Illness Prevention
12.3K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
In primary prevention, actions taken before disease onset prevent the disease from...
12.3K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
465
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
465
01:12Analysis of Population Pharmacokinetic Data
222
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
222
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
119
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
119